Klastersky J
Service de Médecine, H.J. Tagnon, Institut Jules Bordet, Brussells, Belgium.
Curr Opin Oncol. 1998 Jul;10(4):284-90. doi: 10.1097/00001622-199807000-00002.
Febrile neutropenia is a changing syndrome which requires periodic updates as our armamentarium against this condition improves, and the characteristics of the pathogens change. In addition, cost of therapy has become a major issue when designing therapeutic strategies. This article reviews the basis of the current therapeutic approaches to febrile neutropenia, and this information is used to propose an algorithm for the management of this condition taking into consideration, in addition to these medical aspects, cost-effectiveness.
发热性中性粒细胞减少是一种不断变化的综合征,随着我们针对这种病症的治疗手段不断改进以及病原体特征的改变,需要定期更新相关内容。此外,在设计治疗策略时,治疗费用已成为一个主要问题。本文回顾了当前发热性中性粒细胞减少治疗方法的依据,并利用这些信息提出一种针对该病症的管理算法,除了考虑这些医学方面外,还兼顾成本效益。